miR-337-3p and Its Targets STAT3 and RAP1A Modulate Taxane Sensitivity in Non-Small Cell Lung Cancers-Reference-Cited by-同舟云学术

miR-337-3p and Its Targets STAT3 and RAP1A Modulate Taxane Sensitivity in Non-Small Cell Lung Cancers

Published:2012-06-18 Issue:6 Volume:7 Page:e39167
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Du Liqin,Subauste Maria C.,DeSevo Christopher,Zhao Zhenze,Baker Michael,Borkowski Robert,Schageman Jeoffrey J.,Greer Rachel,Yang Chin-Rang,Suraokar Milind,Wistuba Ignacio I.,Gazdar Adi F.,Minna John D.,Pertsemlidis Alexander

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference52 articles.

1. Caesar GJ (50 BC) Commentarii de Bello Gallico

2. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.;AY Chang;J Natl Cancer Inst,1993

3. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.;WK Murphy;J Natl Cancer Inst,1993

4. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.;M Hari;Mol Cancer Ther,2006

5. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.;S Mozzetti;Clin Cancer Res,2005

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors;Expert Opinion on Pharmacotherapy;2024-05-23

2. A review on expression and regulatory mechanisms of miR-337-3p in cancer;Journal of Biomolecular Structure and Dynamics;2024-03-18

3. Involvement of miRNA-337 in Various Cancers;Current Cancer Therapy Reviews;2024-03

4. The role of miRNAs in multiple sclerosis pathogenesis, diagnosis, and therapeutic resistance;Pathology - Research and Practice;2023-11

5. Transcriptional subtypes of glottic cancer characterized by differential activation of canonical oncogenic programming;Head & Neck;2023-09-08